SEC Form 4 · accession 0001209191-15-043030

aTYR PHARMA INC · LIFE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · Other

Period of report

May 12, 2015

Accepted (ET)

May 14, 2015 · 9:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001339970

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	May 12, 2015	C	1,546,126	—	A	1,546,126	I	By Sofinnova Venture Partners IX, L.P.
Common Stock^F3	May 12, 2015	P	320,000	$14.00	A	1,866,126	I	By Sofinnova Venture Partners IX, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series E Redeemable Convertible Preferred Stock^F3,F1,F2	—	May 12, 2015	C	14,968,722	D	—	—	Common Stock	1,546,126	0	I

F1The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-9.6814 basis.
F2Reflects a 1-for 9.6814 stock conversion of the Issuer's Preferred Stock into Common Stock which became effective immediately prior to the closing of the Issuer's initial public offering.
F3The shares are owned by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., Dr. Srinivas Akkaraju, and Dr. Anand Mehra are managing members of SM IX and exercise shared voting and investment power with respect to the shares owned by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.